Life Science Today: Recent Episodes
Noah Goodson, PhD
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
This week, I have an announcement to make.
Find out more athttps://LifeScienceTodayPodcast.com
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyout
Find out more athttps://LifeScienceTodayPodcast.com
Story References
Sanofi/Takeda
UniQure & CSL
Fog Pharma
Merck + Imago
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals
Find out more athttps://LifeScienceTodayPodcast.com
Story References
Indivior + Opiant
Regeneron + CytomX
Rezo
Provention
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
More CRISPR data, oncology wins, and a new player in ophthalmology
Find out more athttps://LifeScienceTodayPodcast.com
Story References
Intellia
Regeneron
Viatris + Oyster Point
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Billion-dollar acquisitions, troubled waters for some biotech’s, and a prosperous outlook for others
Find out more athttps://LifeScienceTodayPodcast.com
Story References
Sumitovant + Myovant
Thermo Fisher + Binding Site Group
Astellas & Taysha
Agios
Vaxctye
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Some statistically significant guidance, seed to acquisition, some biobucks, and the CART of the future.
Find out more athttps://LifeScienceTodayPodcast.com
Story References
FDA
AbbVie + DJS
Roche + Hookipa
Kyverna
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
One biotech is on a roll, another is moving quickly, Amazon money for cancer, and some clinical development news
Find out more athttps://LifeScienceTodayPodcast.com
Story References
DICE
Odyssey
Fred Hutch
Merck (MSD), Merck Story 2
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Biotech’s with a series A, a Series C, some debt financing, and there is even a Biopharma heading for a SPAC
Find out more athttps://LifeScienceTodayPodcast.com
Story References
Nested Therapeutics
Cellarity
Replimune
Estralla Biopharma
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Major Alzheimer’s news, an ALS approval, and expanded therapies for skin conditions
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesEisai + Biogen
Amylyx
Sanofi + Regeneron
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
A $900 raise, gene therapy news, a quick IPO, and merge three for $100M
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesAlnylam, Link 2, Link 3
Intellia Therapeutics
Third Harmonic Bio
Galvanize Therapeutics
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
A critical aesthetics approval, site network buy-up, a very normal oncology biotech, and a busy week for one company.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesRevance
Velocity + MedPharmics
Arsenal
SpringWorks Link 1, Link 2, Link 3
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
A $1.1B acquisition, two FDA approvals, and grants for mRNA vaccines.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesNovo + Forma
Sanofi
Boehringer Ingelheim
Arcturus
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Ophthalmology acquisitions, following the pharma trends, and a move in healthcare that is not technology related.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesAlcon + Aerie
Novartis + Sandoz
Labcorp + RWJBH
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Gene therapy approval, opioid costs continue, a $650M deal, and a $3.5B RNA partnership.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesBluebird
Endo & Pharmacies
Genentech + Jemincare
Merck + Orna
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Spending that COVID money, brain money, Irish money, and another oncology approval.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesPfizerCerevelAbbottAstaZeneca + Daiichi Sankyo
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
This week, we take a break from stories of raising capital, mergers, and FDA approvals to look at the dark side of our industry. What happens when companies fail, people lie, and good drugs make bad lives?
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesZymergen + Ginkgo
Cassava
Teva
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
There’s a SPAC, expanded FDA approval, more of the common, and two Bs, two As
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesZyVersa
Incyte
Revolution
Frontera
CAMP4
ForSight
Auron
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Cell therapy acquisition, royalties sold, biobucks-like deal, successful raise, and Chinese Venture Capital
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesVertex + ViaCyte
Theravance Biopharma
Merck + Orion
Pliant Therapeutics
Qiming
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
FEED DROP - Clinical Research Evolved
Noah and John talk with Dan Agroskin, a managing director at a leading private equity firm with a focus on the clinical research industry. We discuss how investments shape industries, what entrepreneurs should think about private equity, and the forces that drive exceptional business growth.
Find Out MoreDan AgroskinClinical Research EvolvedNoah Goodson, PhD
John Reites
Kyle Ricketts
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Double acquisition, private money, affordable deals, and a surprising $70M launch
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesGalapagos + CellPoint + AboundBio
Radius
Ipsen + Epizyme
DEM Bio
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Crohn’s approval, new VC round, direct offerings, and potential asset sales.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesAbbVie
Third Rock
Scholar Rock
Kyowa Kirin
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Gene therapy, minor legislation, a $625M series D, and four companies raise $373M.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesBlueBird
FDA
Resilience
Corvia, Code, Mineralys, Tessa
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Pharma buys, pharma splits, pharma trades, and oncology biobucks from pharma
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesGSK + Affinivax
Pfizer – Haleon
Regeneron
Roche + Repare
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Pox progress, an oncology acquisition, and we look at $360M worth of biotech funding
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesChimerix, Emergent, SIGA
Merck & Kelun
Inceptor, Laekna, Kriya
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
An $11.6B yes, $11.7B delay, drop the A1C with GLP, and a billion bio-bucks
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesPfizer + Biohaven
Regulators
Lilly
BridgeBio + BMS
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Resets for biotech, antibiotics approval not enough, continued consolidation, and a normal deal
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesZymeworks
Phathom
Catalyst
CenExel
Intercept + Advanz
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Pharma Q1 reports are rolling in, COVID boost turned sustainable, and weight loss battle looms
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesMerck
Sanofi
J&J
ThermoFisher
Novo Nordisk
Eli Lilly
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Drops for reading, a $220M raise, and an acquisition straight out of the movies
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesOrasis
Reify
Blackrock + MindX
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
The FDA asks for more diversity, $1B for injectors, $2B for a one-trick pony, and $68M to make DNA.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesFDA
Antares + Halozyme
GSK + Sierra
Ansa Biotechnologies
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Viral therapies, rare disease approvals, and lab space premiums
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesPfizer + ReViral
Novartis
Charles River + Explora Labs
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Big compensation, mild mergers, a Kite in an updraft, and tightening the biotech belt
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesGinkgo
Eagle + Acacia
Gilead
Taysha/Orchard/Silverback
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
$2 billion in capital raises mostly by companies that start with the letter A.
Find out more athttps://LifeScienceTodayPodcast.com
Story References2seventy Bio
Ascendis
Apellis
Argenx
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Case closed on patents, Alzheimer’s data, generic approvals, and expanded approvals.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesAlexion + Chugai
Biogen
Viatris
AbbVie
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Technology for inclusion, layoffs, oncology approvals, and $200M for a tech platform.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesGilead
AstraZeneca + Merck + Myriad
DNAnexus
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Who owns CRISPR, a collaboration, the classics, and more money for biotech.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesSanofi + Adagene
AbbVie + Syndesi
Atlas
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
CRISPR works, the opioid epidemic makes amends (sort of), and the SPAC that wasn’t
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesIntellia
Purdue PharmaAmicus SPAC
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
The PD1 that lost, biopharma earns FDA approval, and the Biotech market is cool not dead
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesEli Lilly + Innovent Biologics
Agios
TC Biopharm
Blue Water Vaccines
Meihua
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Dragons over unicorns, to CRISPR and beyond, spin-out-and-sell, and expanded approvals.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesArcellx
Intellia + Rewrite
Navitor + Janssen
ViiV
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Bispecific antibodies, ocular oncology, Biogen sells, Lilly Builds, and the treatment of a lifetime
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesGenentech
Immunocore
Biogen
Eli Lilly
TenSixteen
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Psychedelic SPACs, eczema frenzy, bio-outs without the biobucks, back on track, and the mega-deal that wasn’t
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesEleusis
Abbvie/Pfizer/Leo
UCB + Zogenix
Kura
GSK - Unilever
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Oncology partners, Parkinson’s partners, expanded European Commission, expanded FDA, and bacterial vaccines
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesScorpion & AstraZeneca
ABL & Sanofi
Vertex
Cochlear
Vaxcyte
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Devices with tech enablement, nano particles, Chinese approvals, and a massive series B for biotechnology
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesStryker + Vocera
Merck KGaA + Exelead
BeiGene
Eikon
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
We’ve got a new name, gene therapy buyout, a lion of an approval, and an inescapable spotlight.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesNovartis + Gyroscope
Leo
Biogen
Biogen 2
About the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Acquiring the acquired, EHR acquisition, first approvals, and a new fund for the new year
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesCSL + Vifor
Oracle + Cerner
Calliditas
Omega
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Antitrust AI, development AI, expanded approval, mega seeds, and biosimilar SPACs
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesMicrosoft + NuanceRoche + RecursionHeron1EAlvotech
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Double acquisitions in Switzerland, FDA holds and what that means, CMV therapy, rare + oncology continues, BioCryst draws millions, and deer.
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesVifor + Sanifit + Inositec
Kura
Differential Syndrome
Takeda
Aadi
BioCryst
USDA
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Top dollar lab notes, lab consolidation, RNA sells, and two new approval areas
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesBenchling
Labcorp
Novo Nordisk
BioMarin
BioMarin 2
AppliedVR
AppliedVR 2 Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
A giant breaks in two, acquisitions in women’s health, Medicare cost, rare approvals, more CRISPR, and a legacy
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesJohnson & Johnson
Organon
Medicare
PharmaEssentia
Arbor Biotechnologies
Glen de Vries
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Roche and Novartis part ways, Alphabet likes AI, Pfizer 89%, Series A, B, and the money that gets you there
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story ReferencesRoche - Novartis
Alphabet
Pfizer
Parthenon
Antios
Mission Bio
Section 32
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
This week, we have a special bonus interview with Danielle Coe, founder of Black Women in Clinical Research.
Danielle Coe
Black Women in Clinical Research
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Background
Danielle Coe started her career as a lab-based scientist, after learning from a friend about work in clinical research she pivoted her goals. It wasn’t immediate, but she eventually found her way into the industry and has forged a path on the site side clinical research. Through the process she was struck by the lack of women of color. To help decrease this gap and drive diversity through peer-to-peer support, Danielle created Black Women in Clinical Research. The goal? To help other black women start and build careers in clinical research through community support, resume crafting, interview preparation, negation tactics for salary, and more.
Danielle carved time out of her busy schedule to share her story. I really appreciate the way she has turned the challenges she faced into a solution for others and her drive to provide practical solutions, not just nice ideas.
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Unique therapies including anti-opioid overdose, ocular implants, fish skin, UV light, digital therapeutics, and the impact of approvals
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story Referenceshttps://tinyurl.com/Niche-074-1
https://tinyurl.com/Niche-074-2
https://tinyurl.com/Niche-074-3
https://tinyurl.com/Niche-074-4
https://tinyurl.com/Niche-074-5
https://tinyurl.com/Niche-074-6
https://tinyurl.com/Niche-074-7
https://tinyurl.com/Niche-074-8
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
The 26-year pipeline, CMDO divestment, oncology, and movement among COVID19 Therapies
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story References
https://tinyurl.com/Niche-073-1
https://tinyurl.com/Niche-073-2
https://tinyurl.com/Niche-073-3
https://tinyurl.com/Niche-073-4
https://tinyurl.com/Niche-073-5
https://tinyurl.com/Niche-073-6
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Less than spiffy SPACs, big brains big money, Malaria buzz, vaccines, tests, series A, and Voyager gets a renewed lease on life
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story Referenceshttps://tinyurl.com/Niche-072-1
https://tinyurl.com/Niche-072-2
https://tinyurl.com/Niche-072-3
https://tinyurl.com/Niche-072-4
https://tinyurl.com/Niche-072-5
https://tinyurl.com/Niche-072-6
https://tinyurl.com/Niche-072-7
https://tinyurl.com/Niche-072-8
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
$11.5B acquisitions, we play “Who’s on First”, COVID19 therapy news, cancer Vaccines may be on the way, and CAR T for cancer is here to stay
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story Referenceshttps://tinyurl.com/Niche-071-1
https://tinyurl.com/Niche-071-2
https://tinyurl.com/Niche-071-3
https://tinyurl.com/Niche-071-4
https://tinyurl.com/Niche-071-5
https://tinyurl.com/Niche-071-6
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Double approval, double acquisition, $200M for tests, $200M for prostate robots, $450M for $1B worth of gummies
Originally Published as The Niche Podcast.
Find out more athttps://LifeScienceTodayPodcast.com
Story Referenceshttps://tinyurl.com/Niche-070-1
https://tinyurl.com/Niche-070-2
https://tinyurl.com/Niche-070-3
https://tinyurl.com/Niche-070-4
https://tinyurl.com/Niche-070-5
https://tinyurl.com/Niche-070-6
https://tinyurl.com/Niche-070-7
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. You can expect highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
BeiGene’s oncology machine, China oncology pipelines, COVID costs, two new FDA approvals, $5B life science merger, and Hong Kong joins US SPAC party
Find out more athttps://thenichepod.com
Story Referenceshttps://tinyurl.com/Niche-069-1
https://tinyurl.com/Niche-069-2
https://tinyurl.com/Niche-069-3
https://tinyurl.com/Niche-069-4
https://tinyurl.com/Niche-069-5
https://tinyurl.com/Niche-069-6
https://tinyurl.com/Niche-069-7
https://tinyurl.com/Niche-069-8
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
$1.5B deal, $1.9B merger, protein degraders get backing, an old bird has new tricks, and another billion-dollar valuation for CRISPR
Find out more athttps://thenichepod.com
Story Referenceshttps://tinyurl.com/Niche-068-1
https://tinyurl.com/Niche-068-2
https://tinyurl.com/Niche-068-3
https://tinyurl.com/Niche-068-4
https://tinyurl.com/Niche-068-5
https://tinyurl.com/Niche-068-6
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThis week, I go on vacation and give you a special bonus interview with Sam Searcy, founder and CEO of CliniStart and former NC State Senator
Find out more athttps://thenichepod.com
Story Referenceshttps://clinistart.com/
https://www.samsearcy.com/
https://www.linkedin.com/in/samuel-searcy-3462891a4/
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThe Cassava saga, Reify goes big… too big? Humacyte SPAC, vax news you already know, and a new growth hormone therapy – approved!
Find out more athttps://thenichepod.com
Story Referenceshttps://tinyurl.com/Niche-066-1
https://tinyurl.com/Niche-066-2
https://tinyurl.com/Niche-066-3
https://tinyurl.com/Niche-066-4
https://tinyurl.com/Niche-066-5
https://tinyurl.com/Niche-066-6
https://tinyurl.com/Niche-066-7
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastAlphabet buys, uncertain futures, new biotech funds, HIF-2a, PD-1, and a China Biotech emerges.
Find out more athttps://thenichepod.com
Story Referenceshttps://tinyurl.com/Niche-065-1
https://tinyurl.com/Niche-065-2
https://tinyurl.com/Niche-065-3
https://tinyurl.com/Niche-065-4
https://tinyurl.com/Niche-065-5
https://tinyurl.com/Niche-065-6
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThis week, approvals for sleep and seizures across the pond, mRNA finds other SPACs, senior notes for CROs, FTC does a double take, IPOs, and boosters
Find out more athttps://thenichepod.com
Story Referenceshttps://tinyurl.com/Niche-064-1
https://tinyurl.com/Niche-064-2
https://tinyurl.com/Niche-064-3
https://tinyurl.com/Niche-064-4
https://tinyurl.com/Niche-064-5
https://tinyurl.com/Niche-064-6
https://tinyurl.com/Niche-064-7
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastDevice acquisitions, rare disease approvals, COVID success stories, and clinical research ups and downs.
Find out more athttps://thenichepod.com
Story Referenceshttps://tinyurl.com/Niche-063-1
https://tinyurl.com/Niche-063-2
https://tinyurl.com/Niche-063-3
https://tinyurl.com/Niche-063-4
https://tinyurl.com/Niche-063-5
https://tinyurl.com/Niche-063-6
https://tinyurl.com/Niche-063-7
https://tinyurl.com/Niche-063-8
https://tinyurl.com/Niche-063-9
https://tinyurl.com/Niche-063-10
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThis week, look closer – with drops, controlled gene therapy, acquisitions in antibodies, new antifungals, new biosimilars, and several IPOs
Find out more athttps://thenichepod.com
Story Referenceshttps://tinyurl.com/Niche-061-1
https://tinyurl.com/Niche-061-2
https://tinyurl.com/Niche-061-3
https://tinyurl.com/Niche-061-4
https://tinyurl.com/Niche-061-5
https://tinyurl.com/Niche-061-6
https://tinyurl.com/Niche-061-7
https://tinyurl.com/Niche-061-8
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastIn this special bonus episode, Dr. Noah Goodson sits down with biotech founders Dr. Shawn Carbonell and Dr. Brent Witgen to discuss their new founder-friendly biotech incubator Brazen Bio.
Find out more athttps://thenichepod.com
Story Referenceshttps://wefunder.com/brazenbio/
https://www.linkedin.com/company/brazenbio/
https://www.brazen.bio
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastSequencing technology, decentralized Alzheimer’s trials, busts in gene therapy and microbiomes, and a $2.4B oncology collaboration
Find out more athttps://thenichepod.com
Story Referenceshttps://tinyurl.com/Niche-060-1
https://tinyurl.com/Niche-060-2
https://tinyurl.com/Niche-060-3
https://tinyurl.com/Niche-060-4
https://tinyurl.com/Niche-060-5
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
Dopamine deals, Merck vaccine approval, Epipen settlements, billions in buildings, and outsized Oncology IPO.
Story Referenceshttps://tinyurl.com/Niche-059-1
https://tinyurl.com/Niche-059-2
https://tinyurl.com/Niche-059-3
https://tinyurl.com/Niche-059-4
https://tinyurl.com/Niche-059-5
https://tinyurl.com/Niche-059-6
https://tinyurl.com/Niche-059-7
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastMuddy waters of data privacy and genetic databases, antibody-drug conjugate approvals, unabetted wild enthusiasm for CROs, and mobile MRIs go public.
Story Referenceshttps://tinyurl.com/Niche-058-1
https://tinyurl.com/Niche-058-2
https://tinyurl.com/Niche-058-3
https://tinyurl.com/Niche-058-4
https://tinyurl.com/Niche-058-5
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
About The Niche Podcast
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastWelcome to a special bonus episode as we kick off Season 2 the Niche Podcast. I sat down with Dr. Jayne Morgan, the head of the COVID19 task force at Piedmont Healthcare to talk about her career in clinical research.
Sponsorshttps://www.thescopemethod.com
Dr. Morgan on LinkedInhttps://tinyurl.com/Niche-057-1
Dr. Morgan on Instagramhttps://tinyurl.com/Niche-057-2
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
About The Niche Podcast
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThis is the last episode of Season 1 of the Niche Podcast. In line with that, I’ve got some announcements right at the top of the episode. Also, this week, congressional brakes, internal brakes, FDA brakes, and the first human CRISPR data.
Story Referenceshttps://tinyurl.com/Niche-056-1
https://tinyurl.com/Niche-056-2
https://tinyurl.com/Niche-056-3
https://tinyurl.com/Niche-056-4
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastKidney research, pet health, manufacturing is valuable, and a couple of biotech IPOs
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-055-1
https://tinyurl.com/Niche-055-2
https://tinyurl.com/Niche-055-3
https://tinyurl.com/Niche-055-4
https://tinyurl.com/Niche-055-5
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastWe dive deep into Alzheimer’s, Regeneron execs might be overpaid, a merger in clinical research, and the FDA issues a Class 1 recall
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-054-1
https://tinyurl.com/Niche-054-2
https://tinyurl.com/Niche-054-3
https://tinyurl.com/Niche-054-4
https://tinyurl.com/Niche-054-5
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastPending FDA approvals, expanded FDA approvals, new FDA approvals, and a lawsuit about FDA approvals.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-053-1
https://tinyurl.com/Niche-053-2
https://tinyurl.com/Niche-053-3
https://tinyurl.com/Niche-053-4
https://tinyurl.com/Niche-053-5
https://tinyurl.com/Niche-053-6
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastM&A Speed Bumps, “Normal” IPO but not approach, two updates, and FDA gives nod to menstrual bleeding, prostate cancer, and COVID19 monoclonal antibodies.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-052-1
https://tinyurl.com/Niche-052-2
https://tinyurl.com/Niche-052-3a
https://tinyurl.com/Niche-052-4
https://tinyurl.com/Niche-052-5
https://tinyurl.com/Niche-052-6
https://tinyurl.com/Niche-052-7
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastOncology on the move, an industry report looking at broader trends, good news in Alzheimer’s, and another niche oncology therapy approved.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-051-1
https://tinyurl.com/Niche-051-2
https://tinyurl.com/Niche-051-3
https://tinyurl.com/Niche-051-4
https://tinyurl.com/Niche-051-5
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastTwo FDA approvals, cellulite and tattoos, Ginkgo pulls in $2.5B, and Caris massive growth equity for oncology testing.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-50-1
https://tinyurl.com/Niche-50-2
https://tinyurl.com/Niche-50-3
https://tinyurl.com/Niche-50-4
https://tinyurl.com/Niche-50-5
https://tinyurl.com/Niche-50-6
https://tinyurl.com/Niche-50-7
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastCritical intellectual property move by Biden-Harris, Pfizer goes for full approval, SPAC 1, SPAC 2, Regeneron drops big numbers, and an IPO gets punted.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-049-1
https://tinyurl.com/Niche-049-2
https://tinyurl.com/Niche-049-3
https://tinyurl.com/Niche-049-4
https://tinyurl.com/Niche-049-5
https://tinyurl.com/Niche-049-6 Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
Originally Published as The Niche PodcastWelcome to a monthly bonus episode. I sat down with Dr. Amir Kalali, the co-chair of the Decentralized Trials & Research Alliance (DTRA) – a clinical research coalition of the most influential companies in the field to talk about decentralized research and collaborating for our success as an industry.
2:35 – From CRO to CNS Summit
10:30 – Ramping up DTRA
12:29 – The Ramp of Decentralized Trials
15:50 – What will stick after the pandemic?
19:28 – How different are decentralized trials really?
22:42 – Technology traps and Hybrid Trials
25:12 – How are trust networks changing with decentralized trials?
29:09 – What is the roll of DTRA in the industry?
33:28 – Ecosystems are interconnected, how can we partner within the clinical research/pharma ecosystem?
36:10 – What is the future of the DTRA?
Subscribe@https://thenichepod.com
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://cnssummit.org
https://dtra.org
https://www.linkedin.com/in/amirkalali/
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
Originally Published as The Niche PodcastThe FDA slaps wrists and takes names, Farxiga expands FDA approval, BioVie makes cash-light acquisition, Pfizer targets fungus, and one IPO down, another to go.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-047-1
https://tinyurl.com/Niche-047-2
https://tinyurl.com/Niche-047-3
https://tinyurl.com/Niche-047-4
https://tinyurl.com/Niche-047-5
https://tinyurl.com/Niche-047-6
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastBillion-dollar amendments, billion-dollar funds, GSK gets oncology nod from FDA, and two stories in clinical research.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-046-1
https://tinyurl.com/Niche-046-2
https://tinyurl.com/Niche-046-3
https://tinyurl.com/Niche-046-4
https://tinyurl.com/Niche-046-5
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastMassive acquisitions in the CRO space, Trodelvy 2x, diagnostic acquisitions, Merck closes COVID vaccine program, Xolair get’s self-injection nod, and tiny robots go for massive SPAC.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-045-1
https://tinyurl.com/Niche-045-2
https://tinyurl.com/Niche-045-3
https://tinyurl.com/Niche-045-4
https://tinyurl.com/Niche-045-5
https://tinyurl.com/Niche-045-6
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastGilead gets FDA approval in oncology, Bio-Techne acquires Asuragen, AI for tumor targeting, and Achilles completes $175M IPO.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-044-1
https://tinyurl.com/Niche-044-2
https://tinyurl.com/Niche-044-3
https://tinyurl.com/Niche-044-4
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastCharles River acquires Retrogenix, IQVIA fully acquires Q2 Solutions, Agios sells $1.8B in oncology, and Alloy forges a $75M series C.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-043-1
https://tinyurl.com/Niche-043-2
https://tinyurl.com/Niche-043-3
https://tinyurl.com/Niche-043-4
https://tinyurl.com/Niche-043-5
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThis is our March bonus episode. I sit down with Dr. Benjamin Schwartz an orthopedic surgeon and digital health expert. We talk digital integration, healthcare cost, and how you can get involved in the space.
Sponsorshttps://www.thescopemethod.com
Guest Referenceshttps://www.benschwartzmd.com/
https://www.linkedin.com/in/ben-schwartz-md/
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastMergers in precision oncology testing, Medtronic breakthrough valve replacement, Gyroscope raises capital for AMD, and small molecule genetic treatments get $240M IPO.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-041-1
https://tinyurl.com/Niche-041-2
https://tinyurl.com/Niche-041-3
https://tinyurl.com/Niche-041-4
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastA new MS therapeutic, Fujifilm picks CDMO facility site, consolidation in medical services, and a new oncology startup.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-040-1
https://tinyurl.com/Niche-040-2
https://tinyurl.com/Niche-040-3
https://tinyurl.com/Niche-040-4
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast92% reduction in COVID mortality, AVEO gets FDA approval, Takeda acquires Maverick and targets emerging markets, and AgomAb raises $74M Series B for regenerative medicine.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-039-1
https://tinyurl.com/Niche-039-2
https://tinyurl.com/Niche-039-3
https://tinyurl.com/Niche-039-4
https://tinyurl.com/Niche-039-5
https://tinyurl.com/Niche-039-6
https://tinyurl.com/Niche-039-7
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastAmgen nabs Five Prime Therapeutics in $1.9B deal, KemPharm ligates their way out of debt with ADHD, three failed COVID19 pipelines, and Colfax follows 2019 merger with corporate split.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/niche-038-1
https://tinyurl.com/niche-038-2
https://tinyurl.com/niche-038-3
https://tinyurl.com/niche-038-4
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastI sit down with Dr. Mitrani, the Chief Scientific Officer for Organicell, a clinical stage biopharma company focused on regenerative medicine. Their leading product, Zofin is currently in early clinical trials for the treatment of COVID19. Eventually it may be a therapeutic for long haulers.
Key Talking Points2:43 - Dr. Mitrani’s Journey to regenerative medicine
5:30 - From stem cells to nano medicine
8:12 - What is Zofin and how might it work?
9:46 - Pivoting into COVID19
11:42 - Following the science from stem cells to nano infusions
14:21 - Doing science is hard but we follow the data
19:59 - How following scientific data for years prepares you to pivot in response to crisis
25:40 - What trends have stood the test of time?
30:27 - How novel therapeutic spaces require novel approaches to product validation
34:11 - The work that is being done for COVID19 long-haulers
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://organicell.com/
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastPRA acquired by Icon, Johnson & Johnson’s vaccine approved, Oncopeptides’ earns FDA approval, Roivant acquires Silicone Therapeutics, and Merck acquires Pandion.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/niche-036-1
https://tinyurl.com/niche-036-2
https://tinyurl.com/niche-036-3
https://tinyurl.com/niche-036-4
https://tinyurl.com/niche-036-5
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastEli Lilly bets on RIPK1, Charles River spends $875M on cell and gene therapy, Adjuvant Capital gets who’s who in backing, you can now buy an at-home COVID19 testing kit whenever you want, and Abbott does it again for the 389th time.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/niche-35-1https://tinyurl.com/niche-35-2https://tinyurl.com/niche-35-3https://tinyurl.com/niche-35-4https://tinyurl.com/niche-35-5Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastGenentech’s next tech, GSK divests to invest, Bristol Myers Squibb checks oncology, Cassava Sciences raises capital, Libtayo gets expanded FDA approval, and Hyperfine turns on hyperdrive.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-34-1
https://tinyurl.com/Niche-34-2
https://tinyurl.com/Niche-34-3
https://tinyurl.com/Niche-34-4
https://tinyurl.com/Niche-34-5
https://tinyurl.com/Niche-34-6
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastTwo Mercks - three stories, Paraxel gets genomes, Genomes get Money, and 2021 is the year of the upsized public offering.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-33-Merck1
https://tinyurl.com/Niche-33-Merck2
https://tinyurl.com/Niche-33-Merck3
https://tinyurl.com/Niche-33-2
https://tinyurl.com/Niche-33-3
https://tinyurl.com/Niche-33-4
https://tinyurl.com/Niche-33-5
https://tinyurl.com/Niche-33-6
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastBiogen gets punted but it’s good, lupus breakthroughs, Senseonics raises capital, and Novavax and Johnson & Johnson… and Janssen.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche-032-1
https://tinyurl.com/Niche-032-2
https://tinyurl.com/Niche-032-3
https://tinyurl.com/Niche-032-4
https://tinyurl.com/Niche-032-5
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThis is our January interview bonus. I sit down with John Reites, founder and CEO of Thread Research to discuss eCOA, decentralized clinical trials past, present, and future, and how you can think about a decentralized approach to your project.
Timeline
1:00 – The last 10 years of decentralized research
3:15 – The current regulatory landscape and variability in the industry
5:32 – Moving into the life sciences from another spaces
8:28 – Breakdown of eCOA and the subcategories you need to know about
12:36 – Are all trials becoming decentralized?
15:40 – Decentralized trials in the future
22:04 – Data Security with eCOA and decentralized trials
25:58 – Challenges implementing international and multinational decentralized trials
32:00 – Steps you should take to make your trial decentralized-ready
Sponsorshttps://www.thescopemethod.com
More on John Reiteshttps://www.threadresearch.com
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThermo Fisher Scientific spends a billion, Boston Scientific also spends a billion and gets FDA approval, Verve pulls $94 million for CRISPR in humans, and Vera raises $80 million for Berger’s disease
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche030-1
https://tinyurl.com/Niche030-2
https://tinyurl.com/Niche030-3
https://tinyurl.com/Niche030-4
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast100 million vaccines, EvoQ’s NanoDisk, Merck gets FDA priority, and startups in wearables, startups in diagnostics.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://tinyurl.com/Niche029-1https://tinyurl.com/Niche029-2
https://tinyurl.com/Niche029-3https://tinyurl.com/Niche029-4
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastTurning CAR T on and off, Fujifilm’s $2 billion investment, Affinivax raises $226 million, and startups to watch
Sponsorshttps://www.thescopemethod.com
Story References10.1126/scitranslmed.abb6295
https://affinivax.com/affinivax-announces-226-million-series-c-financing-to-advance-its-pipeline-of-novel-maps-vaccines-targeting-infectious-diseases/
https://www.fujifilm.com/us/en/news/Fujifilm_to_Invest_2B_for_Cell_Culture_Manufacturing_Site
https://www.businesswire.com/news/home/20210105005224/en/IconOVir-Bio-Raises-77-Million-in-Series-A-Financing-to-Develop-Next-Generation-Oncolytic-Viruses-to-Treat-Solid-Tumors
https://www.lexeotx.com/
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastAstraZeneca and W.H.O., vaccine I-told-you-so’s, Phitonex acquired by ThermoFisher, and Axsome reports success in migraine relief.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://www.rttnews.com/3157074/astrazeneca-s-covid-19-vaccine-cleared-by-expert-panel-in-india.aspx?refresh=1
https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access
https://www.bbc.com/news/health-55280671
https://thermofisher.mediaroom.com/2020-12-31-Thermo-Fisher-Scientific-Acquires-Programmable-Dye-Platform-Pioneer-Phitonex
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-positive-efficacy-and-safety-0?field_nir_news_date_value[min]=
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastTrends in science from investors and immune-oncology to decentralized trials and basic research, we look back on 2020
Sponsorshttps://www.thescopemethod.com
Story Referenceswww.thenichepod.com
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastCOVID updates, ERT & Bioclinica merge, Philips acquires BioTelemetry, and augmented reality surgeries.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://www.ellumehealth.com/2020/12/15/fda-authorizes-ellume-covid-19-home-test-as-first-over-the-counter-fully-at-home-diagnostic-test/
Wang et al., 2019 - https://pubs.acs.org/doi/10.1021/acsomega.9b00657
https://www.ert.com/featured-news/ert-and-bioclinica-to-merge-creating-a-global-leader-in-clinical-trial-endpoint-technology/
https://www.philips.com/a-w/about/news/archive/standard/news/press/2020/20201218-philips-to-become-a-global-leader-in-patient-care-management-solutions-for-the-hospital-and-the-home-through-the-acquisition-of-biotelemetry-inc.html
https://www.prnewswire.com/news-releases/seeing-is-believing-hospital-for-special-surgery-first-in-us-to-use-augmented-reality-platform-for-knee-replacement-301195275.html
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastVaccines are here, capitalizing on capital with IPOs, and Gilead targets Hepatitis D.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19
https://www.abcellera.com/news/2020-12-10-abcellera-announces-pricing-of-ipo
https://www.certara.com/pressrelease/certara-announces-pricing-of-its-upsized-initial-public-offering/
https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-upsized-pricing-initial
https://www.nanobiotix.com/wp-content/uploads/2020/12/PR-Pricing.pdf
https://www.gilead.com/news-and-press/press-room/press-releases/2020/12/gilead-sciences-to-acquire-myr-gmbh
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastEverlywell expands at-home testing, Bayer and Atara strike deal, and Moderna heads to the FDA.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://www.prnewswire.com/news-releases/everlywell-announces-175-million-financing-to-expand-consumer-lab-testing-and-digital-health-offerings-301185355.html
https://media.bayer.com/baynews/baynews.nsf/id/Bayer-Atara-Biotherapeutics-enter-strategic-collaboration-generation-mesothelin-targeted-CAR-T?Open&parent=news-overview-category-search-en&ccm=020
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThis week, we take a thanksgiving break from the news cycle to bring you a special interview with a COVID survivor and healthcare worker, Trenton Barrick. He shares an inside perspective on the healthcare industry as well as his personal experience being hospitalized with COVID19.
Sponsorshttps://www.thescopemethod.com
Trenton's Websitehttps://www.nmtworks.com/
Aphasia Choir
https://singaphasia.com/
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastPfizer submits to the FDA, how mRNA vaccines work, and Novartis drops a billion, but really only $50 million
Story Referenceshttps://www.biospace.com/article/pfizer-and-biontech-to-submit-covid-19-vaccine-to-fda-for-emergency-use-today/
https://www.biospace.com/article/releases/stoke-therapeutics-announces-pricing-of-97-5-million-public-offering/
https://www.novartis.com/news/media-releases/novartis-secures-exclusive-rights-potential-acute-respiratory-distress-syndrome-cell-therapy
Sponsorshttps://www.thescopemethod.com
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastCOVID19 vaccine news, an app to stop nightmares, Agios targets Sickle Cell disease, and Silverback files to go public.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy
https://night-ware.com/news
https://investor.agios.com/news-releases/news-release-details/agios-announces-fda-orphan-drug-designation-granted-mitapivat-0
https://sec.report/Document/0001193125-20-290236/
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastAducanumab skeptics, Novo Nordisk and Merck make acquisitions, but first a market update.
Sponsorshttps://www.thescopemethod.com
Story References
https://www.sciencemag.org/news/2020/11/biogen-s-alzheimer-s-drug-candidate-takes-beating-fda-advisers
https://www.merck.com/news/merck-announces-third-quarter-2020-financial-results/
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=33374
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastSyneos Health acquires Synteract, Apellis strikes a billion-dollar deal, and clinical trial patient enrollment, but first a market update.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://www.investor.syneoshealth.com/news-releases/news-release-details/syneos-health-acquire-synteract-top-cro-provider-emerging
https://www.prnewswire.com/news-releases/new-greenphire-data-indicates-clinical-trial-industrys-swift-rebound-patient-enrollment-reaches-pre-pandemic-levels-301159557.html?tc=eml_cleartime
https://investors.apellis.com/news-releases/news-release-details/apellis-and-sobi-enter-collaboration-global-co-development-and
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThis week, siteless with vision, IQVIA back on track, 36%, convalescent plasma, and Remdesivir approved.
Sponsors
https://www.thescopemethod.com
Story References
https://www.businesswire.com/news/home/20201020005645/en/LabCorp-Transforms-the-Clinical-Trial-Experience-And-Streamlines-the-Drug-Development-Process
https://www.businesswire.com/news/home/20201020005345/en/IQVIA-Reports-Third-Quarter-2020-Results-Raises-Full-Year-2020-Guidance-and-Provides-2021-Outlook
https://www.prnewswire.com/news-releases/thermo-fisher-scientific-reports-third-quarter-2020-results-301156312.html
https://www.bmj.com/content/371/bmj.m3939
https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastFailures in sickle-cell therapy, CRO mergers in Asia, Praxis IPO, and wasp venom.
Sponsors
https://www.thescopemethod.com
Story References
https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-phase-2-strong-scd-study-results-patients
https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-positive-data-iw-6463-cns-translational
https://novotech-cro.com/news/asia-pacific-has-record-year-clinical-trials-according-novotech
https://investors.praxismedicines.com/press-releases
https://www.pnas.org/content/early/2020/10/07/2012379117
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastNobel prizes, clinical trials for tinnitus, Takeda’s billion-dollar deal, and the White House keeps science political
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://www.nobelprize.org/prizes/chemistry/2020/summary/
https://stm.sciencemag.org/content/12/564/eabb2830
https://www.nytimes.com/2020/10/05/us/politics/coronavirus-vaccine-guidelines.html
https://www.businesswire.com/news/home/20201008005340/en/
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastBristol Myers strikes a $13 billion deal, presidential experiments, the NIH funds under-represented testing, and Sophia Genetics raises $110 million.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://www.businesswire.com/news/home/20201005005381/en/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash
https://www.sciencemag.org/news/2020/10/heres-what-known-about-president-donald-trump-s-covid-19-treatment
https://www.nih.gov/news-events/news-releases/nih-assess-expand-covid-19-testing-underserved-communities
https://www.sophiagenetics.com/en_US/news/media-mix/details/news/sophia-genetics-raises-110-million-in-oversubscribed-new-funding-round.html
Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastAnother Alzheimer’s failure, COVID19 updates, two stories in the supplements space, and Taysha goes public.
Sponsors
https://www.thescopemethod.com
Story References
https://ir.acimmune.com/news-releases/news-release-details/ac-immune-reports-top-line-results-tauriel-phase-2-trial
https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1.full.pdf
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30417-4
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239799
https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-pricing-initial-public-offering
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastFinch does probiotics the expensive way, lipid nanoparticles, a followup on transparency, and LAVA gains immuno-therapy support.
Sponsorshttps://www.thescopemethod.com
Story Referenceshttps://www.businesswire.com/news/home/20200916005915/en/Moderna-and-Vertex-Establish-New-Collaboration-to-Treat-Cystic-Fibrosis-Using-Gene-Editing
https://finchtherapeutics.com/blog/finch-therapeutics-announces-90-million-financing
https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf
https://www.businesswire.com/news/home/20200916005913/en/LAVA-Therapeutics-Announces-83-million-Series-C-Financing-to-Advance-Novel-Immuno-Oncology-Programs
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastThis week, vaccines and shark statistics, are noses the ultimate pipedream, and eye drops to replace eye-glasses.
Sponsors
https://www.thescopemethod.com
Story References
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html
https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html
https://www.globenewswire.com/news-release/2020/09/10/2091685/0/en/Satsuma-Pharmaceuticals-Announces-Topline-Results-from-EMERGE-Phase-3-Trial-of-STS101-for-the-Acute-Treatment-of-Migraine.html
https://www.orasis-pharma.com/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastRoche earns FDA approval for a combined flu/COVID diagnostic, I-Mab signs with Abbvie for $2 billion, PPD partners to treat lupus, and BioNTech/Pfizer add more COVID candidates while Moderna adds bad press.
Sponsorswww.thescopemethod.com
Story Referenceshttps://www.businesswire.com/news/home/20200903005517/en/PPD-Lupus-Therapeutics-Collaborate-Support-Lupus-Clinical
https://www.fiercebiotech.com/biotech/pfizer-biontech-quietly-usher-a-5th-covid-19-jab-into-clinic-analyst
https://www.npr.org/2020/09/04/908305074/bad-optics-or-something-more-moderna-executives-stock-sales-raise-concerns
https://www.roche.com/media/releases/med-cor-2020-09-04.htm
https://www.usnews.com/news/us/articles/2020-09-02/us-nih-awards-nine-companies-129-million-to-scale-up-covid-19-testing
Music by Luke Goodsonwww.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastJohnson & Johnson acquires Momenta, the White House and FDA disagree, and the emergence of decentralized clinical trial management.
Sponsorswww.thescopemethod.com
Story Referenceshttps://www.momentapharma.com/investors-and-news/press-releases/press-releases-details/2020/Momenta-Enters-Definitive-Agreement-with-Johnson--Johnson/
https://www.hhs.gov/coronavirus/testing/recission-guidances-informal-issuances-premarket-review-lab-tests/index.html
http://www.science37.com/solutions/
Music by Luke Goodsonwww.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastSamsung Biologics builds big, Modern (again), microparticles for timed-release chemotherapy, and Qiagen says ‘no’ to acquisitions.
Sponsorswww.thescopemethod.com
Story Referenceshttps://samsungbiologics.com/front/en/mediaCenter/pressReleasesView.do?boardSeq=781&schBoardCtgryCcd=&schString=&schBoardYear=&boardDtm=1597071600000&page=1#
https://investors.modernatx.com/news-releases
https://stm.sciencemag.org/content/12/556/eaaz6606
https://www.fiercebiotech.com/medtech/thermo-fisher-s-12-5b-deal-for-qiagen-flops-as-covid-19-test-demand-lights-new-path-forward
Music by Luke Goodsonwww.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastBiogen and Denali partner for Parkinson’s, the US pushes American-based drug manufacturing, and the secret to Parasitic Sexual Partners uncovered.
Sponsorswww.thescopemethod.com
Story Referenceshttps://investors.biogen.com/news-releases/news-release-details/biogen-and-denali-collaborate-lrrk2-program-parkinsons-disease
https://science.sciencemag.org/content/early/2020/07/29/science.aaz9445
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832911/
https://www.whitehouse.gov/presidential-actions/executive-order-ensuring-essential-medicines-medical-countermeasures-critical-inputs-made-united-states/
Music by Luke Goodsonwww.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastWe review a few of the big winners from operation warp speed, Merck continues to be quietly successful, and a new CAR T treatment, Tecartus, gets FDA approval.
Sponsorswww.thescopemethod.com
Story Referenceshttps://s21.q4cdn.com/488056881/files/doc_financials/2020/q2/Merck-2Q20-Earnings-News-Release.pdf
https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/us-fda-approves-kites-tecartus-the-first-and-only-car-t-treatment-for-relapsed-or-refractory-mantle-cell-lymphoma
https://www.hhs.gov/about/news/index.html
Music by Luke Goodsonwww.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastAbbott and the FDA develop digital healthcare, Roche gives us some market insight, and we look at Encoded’s approach to gene therapy.
Sponsorswww.thescopemethod.com
Story Referenceshttps://www.roche.com/dam/jcr:5c6df314-831e-4601-9f72-617d28d05e1e/en/23072020_MR_Q2_EN.pdf
https://abbott.mediaroom.com/2020-07-23-Abbott-Receives-FDA-Approval-for-iOS-Compatible-App-Allowing-People-Living-With-Chronic-Pain-and-Movement-Disorders-to-Personalize-Therapy-Via-Their-Mobile-Device
https://encoded.com/encoded-therapeutics-announces-135-million-series-d-financing-to-support-first-clinical-trials-in-scn1a-dravet-syndrome-and-advance-preclinical-pipeline-of-gene-therapies-for-debilitating-neurologic/
Music by Luke Goodsonwww.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastToday on The Niche, big deals in Chinese big-pharma as BeiGene raises another $2 billion, Biogen and Moderna both release papers on crucial clinical trials, and a new cell-type could play a pivotal role in rheumatoid arthritis.
Sponsorswww.thescopemethod.com
Story Referenceshttp://ir.beigene.com/static-files/ec5456b7-8cc2-4b88-8a65-e7d727a0b574
https://www.mayoclinic.org/diseases-conditions/amyotrophic-lateral-sclerosis/symptoms-causes/syc-20354022
https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-interim-data-its-phase-12-clinical-study
https://www.nejm.org/doi/full/10.1056/NEJMoa2003715
https://www.nejm.org/doi/full/10.1056/NEJMoa2004114?rss=searchAndBrowse
https://www.nejm.org/doi/full/10.1056/NEJMoa2022483
Music by Luke Goodsonwww.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastToday on The Niche Pod, Biogen has submitted their Alzheimer’s drug aducanumab to the FDA, we take a look at the fate of PPD since their February IPO, and explore Gilead’s not-a-claim claims on their COVID-19 treatment.
Sponsors
www.thescopemethod.com
Story Referenceshttps://doi.org/10.1016/j.cct.2018.01.003
https://www.ppd.com/
https://www.businesswire.com/news/home/20200514005477/en/PPD-Honored-Quality-Capabilities-CRO-Leadership-Awards
https://www.clinicaltrialsarena.com/comment/biogen-aducanumab-fda-approval-alzheimers/
https://www.fiercebiotech.com/biotech/a-test-for-hahn-s-fda-biogen-submits-controversial-alzheimer-s-drug-aducanumab
https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19
Music by Luke Goodsonwww.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche PodcastToday on The Niche we will be discussing two deaths in a gene therapy trial, new COVID-19 vaccine guidelines from the FDA, and recent developments in CRISPR-Cas gene editing technologies.
Story References
https://www.liebertpub.com/doi/10.1089/hum.2020.182
https://www.fda.gov/media/139638/download
https://apnews.com/dacdc8bc428dd4df6511bfa259cfec44
https://doi.org/10.1126/science.abb6151Music by Luke Goodson
https://soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.